Clinical Trials Browser

Interventional × Has results × capivasertib × Clear all

NCT04439123 2026-05-06

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Phase 2 Active not recruiting

35 enrolled 10 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT03660826 2026-05-04

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Phase 2 Active not recruiting

288 enrolled 21 charts

Carcinosarcoma, Carcinoma, Endometrioid

NCT04305496 2026-04-30

CAPItello-291

Phase 3 Active not recruiting

818 enrolled 19 charts 1 FDA

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT03742102 2026-04-24

BEGONIA

Phase 1/2 Active not recruiting

243 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT05008055 2024-12-20

CAPITAL

Phase 2 Completed

30 enrolled 15 charts

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02576444 2022-12-28

OLAPCO

Phase 2 Terminated

67 enrolled 10 charts

Neoplasms

NCT01895946 2016-05-25

OAK

Phase 1 Completed

33 enrolled 14 charts

Advanced Solid Malignancy,